Snowball logo
logo
ABIO

ARCA biopharma, Inc

ABIO • NASDAQ Не торгуется
-- $0,00 $  (0%)
Оценка
EPS
-5,88
Рост
Чистый доход, YoY
-179,54%
FCF, YoY
-279,54%
Другое
Размер лота
1 шт.
О компании
Тикер
ABIO
ISIN
US00211Y5069
Страна
США
Сектор (GICS)
Здравоохранение
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Часто задаваемые вопросы

В каком секторе работает ARCA biopharma, Inc (ABIO)?

ARCA biopharma, Inc относится к сектору Здравоохранение.

Выплачивает ли ARCA biopharma, Inc (ABIO) дивиденды?

Нет, ARCA biopharma, Inc не выплачивает дивиденды.